The Australian share market has been under pressure recently as global uncertainty and geopolitical tensions weigh on investor sentiment.
Market pullbacks can feel uncomfortable. But they also create opportunities to buy high-quality companies at lower prices.
After the latest slide in the S&P/ASX 200 Index (ASX: XJO), a few standout businesses are starting to look increasingly attractive to long-term investors.
Here are 3 ASX shares I believe could offer compelling value right now.
Image source: Getty Images
Xero Ltd (ASX: XRO)
The Xero share price is currently up 0.58% to $83.90.
Despite today's modest rise, the accounting software company remains well below its previous highs. The stock has fallen over the past year as investors rotated away from high-growth tech companies.
That pullback may be creating an opportunity.
Xero operates one of the world's leading cloud accounting platforms for small and medium-sized businesses. Its software allows companies to manage invoicing, payroll, payments, and financial reporting through a simple online interface.
The business has built a strong presence across Australia, New Zealand, and the United Kingdom, while continuing to expand in North America.
What makes Xero particularly attractive is its growing ecosystem. Beyond accounting software, the platform integrates with a wide range of financial tools and business applications, making it increasingly embedded in customers' day-to-day operations.
With millions of subscribers already on the platform, Xero still has significant room to grow globally.
CSL Ltd (ASX: CSL)
The CSL share price is currently up 2.06% to $145.15.
CSL is one of Australia's most successful healthcare companies and a global leader in biotechnology.
The company develops and manufactures treatments for serious diseases, including immune disorders, haemophilia, and respiratory conditions. Its products are used by patients in more than 100 countries.
Despite its strong global position, CSL shares have struggled over the past year and are now trading near multi-year lows.
A range of factors have weighed on the stock, including higher plasma collection costs and operational pressures across parts of the business.
However, long-term demand for CSL's therapies remains strong as healthcare needs grow worldwide.
If earnings growth begins to accelerate again, the current valuation could prove very attractive.
Pro Medicus Ltd (ASX: PME)
The Pro Medicus share price is currently up 6.58% to $140.15.
Pro Medicus develops medical imaging software used by hospitals and healthcare providers around the world. Its flagship Visage platform enables clinicians to quickly and efficiently view and analyse complex imaging data.
The company has built a reputation for winning large contracts with leading healthcare institutions, particularly in the United States.
Although Pro Medicus shares surged in recent years, the stock has come under pressure in 2026.
That weakness could represent an opportunity for investors focused on healthcare stocks.
